Prospective data collection for perioperative outcomes might increase awareness of surgical results obtained for patients with prostate cancer (PCa) undergoing robot-assisted radical prostatectomy (RARP).
The Young Academic Urologists (YAU) recently appointed internationally-known experts Prof. Véronique Phé (FR) as Chairman and Mr. Nadir Osman (GB) as Vice-Chairman of the YAU Working Group Functional Urology. A professor of urology as well at the University Hospital La Pitié-Salpêtrière, Prof. Phé specialises in urinary incontinence, neuro-urology, voiding disorders, organ prolapse or descent and […]
Upper urinary tract urothelial carcinoma (UTUC) constituted 5-10% of urothelial carcinomas. The management of UTUC has significantly changed in the last decade with the introduction of neoadjuvant chemotherapy options and kidney-sparing surgery (KSS) as an alternative to radical nephroureterectomy (RNU). Studying the trends in incidence, management approaches, and survival outcomes from large-scale cancer registries can […]
New unified organization is a major win for prostate cancer patients, survivors, families, and medical professionals San Francisco, CA (UroToday.com) — The prostate cancer community will have a new patient-centric powerhouse in its corner with the coming merger of ZERO – The End of Prostate Cancer and Us TOO International. The unification of these two […]
Objective: To assess the activity and safety of sequential lutetium‐177 (177Lu)‐PSMA‐617 and docetaxel vs docetaxel on a background of androgen deprivation therapy (ADT) in men with de novo metastatic hormone‐naïve prostate cancer (mHNPC).
To review perioperative, renal functional, and oncological outcomes of the kidney split technique in performing partial nephrectomy (PN) to resect completely endophytic renal tumors. All consecutive patients who underwent open PN with kidney split between 2015 and 2019 at our institution were included.
Non-clear cell renal cell carcinoma (nccRCC) accounts for ≤20% of RCC cases. Lenvatinib (a multitargeted tyrosine kinase inhibitor) in combination with everolimus (an mTOR inhibitor) is approved for the treatment of advanced RCC after one prior antiangiogenic therapy.
Several studies have invariably shown that the risk of Grade Group (GG) upgrading between biopsy and radical prostatectomy (RP) is higher in elderly men. Whether this is due to a real biological effect or to a diagnostic bias is still unknown.
Prior studies have shown that pathologic complete response at radical cystectomy, a significant prognostic factor, can be attributed to both neoadjuvant chemotherapy (NAC) and high-quality transurethral resections (TURBT) prior to NAC.
Focal therapy (FT) with its favorable side-effect profile represents an option between active surveillance and traditional whole-gland treatment in localized prostate cancer (PCa). Consensus statements recommend eligibility criteria based on magnetic resonance imaging (MRI)-targeted and systematic combination biopsy.
